1. Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials. Issue 4 (5th April 2022) Authors: Kang, Yoon-Koo; Reck, Martin; Nghiem, Paul; Feng, Yan; Plautz, Gregory; Kim, Hye Ryun; Owonikoko, Taofeek K; Boku, Narikazu; Chen, Li-Tzong; Lei, Ming; Chang, Han; Lin, Wen Hong; Roy, Amit; Bello, Akintunde; Sheng, Jennifer Journal: Journal for immunotherapy of cancer Issue: Volume 10:Issue 4(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451. Issue 12 (20th April 2021) Authors: Owonikoko, Taofeek K.; Park, Keunchil; Govindan, Ramaswamy; Ready, Neal; Reck, Martin; Peters, Solange; Dakhil, Shaker R.; Navarro, Alejandro; Rodríguez-Cid, Jerónimo; Schenker, Michael; Lee, Jong-Seok; Gutierrez, Vanesa; Percent, Ivor; Morgensztern, Daniel; Barrios, Carlos H.; Greillier, Laurent... Journal: Journal of clinical oncology Issue: Volume 39:Issue 12(2021) Page Start: 1349 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗